Alvogen, Inc. CEO Robert Wessman has tightened his grip on the Icelandic firm’s budding US business after buying up a 17% stake via Aztiq Pharma, the private equity fund Wessman leads.
Having completed a $100m financing round, led by Morgan Stanley and subscribed to by “international institutional investors,” Aztiq – which comprises both individual investors and major funds
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?